Vaccine maker Panacea Biotec has agreed to buy 19.9% in US-based PharmAthene for $13.1 mn. Panacea will route the acquisition through a wholly-owned subsidiary Kelisia Holdings. PharmAthene is developing medical products against biological and chemical threats. Kelisia Holdings will purchase approximately 3.73 mn shares of PharmAthene common stock at $3.50 per share and will also receive warrants to purchase up to 2.75 mn additional shares of PharmAthene at $5.10 per share. The transaction is expected to close on or before October 20, 2008, a Panacea Biotec release said. […]